HPV RELATED OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for HPV RELATED OROPHARYNGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HPV RELATED OROPHARYNGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HPV RELATED OROPHARYNGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Mid-treatment PET scan may allow safer, lower radiation for throat cancer
Disease control OngoingThis study is testing whether a PET scan taken partway through radiation treatment can identify patients with HPV-related throat cancer who can safely receive a lower dose of radiation. The goal is to reduce side effects while still controlling the cancer. About 120 adults with s…
Matched conditions: HPV RELATED OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Immunotherapy before surgery: a new hope for HPV throat cancer?
Disease control TerminatedThis phase 2 trial is testing whether the immunotherapy drug atezolizumab, given before surgery, can help treat HPV-related throat cancer that can be removed. About 20 adults with stage I oropharyngeal cancer will receive two doses of atezolizumab followed by standard surgery. Th…
Matched conditions: HPV RELATED OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could less radiation be better for some throat cancer patients?
Symptom relief OngoingThis study is testing whether giving less radiation to the lymph nodes can reduce side effects for people with low-risk HPV-related throat cancer. The goal is to see if doctors can safely skip radiation to some lymph node areas without increasing the chance of the cancer coming b…
Matched conditions: HPV RELATED OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC